Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

Updated June 5th, 2021

Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

A major new study has found that for women with early stage breast cancer classified as (HER2)–negative, who also have one of the mutations from the BRCA gene, a relatively new class of drugs called PARP Inhibitors significantly extends life after initial treatment.

NOW
PLAYING
FDA Approves Combination of Keytruda & Lenvima For Treatment Of Advanced Uterine Cancer: What Women Need To Know
NOW
PLAYING
Remembering 'Top Chef's' Fatima Ali, Who Passed 2 Years Ago From Cancer: Has There Been Any Progress On Ewing Sarcoma Since?
NOW
PLAYING
Tik Tok Star Nanny Maw Raises $225k For Mom's Breast Cancer Battle
NOW
PLAYING
Do You Have a Question About Mental Health & Cancer-- Ask Dr. Strongin-- A New Column From SurvivorNet
NOW
PLAYING
Iowa Woman Found Stage 2 Breast Cancer After Getting COVID-19 Shot: 'As Much as COVID Sucked, It Saved Me'
NOW
PLAYING
4 Major Cancer Treatment Advances Happened This Week. Here's What You Missed.

SurvivorNetTV.
Hope. Science.
Inspiration.

WATCH NOW
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.